In collaboration with YUMAB, scientists from Merck KGaA have developed a PROTAC-Antibody shuttle (PROxAb) to improve efficacy and therapeutic applicability of PROTACs.
In collaboration with YUMAB, scientists from Merck KGaA have developed a PROTAC-Antibody shuttle (PROxAb) to improve efficacy and therapeutic applicability of PROTACs.
